ReviewDiscover oncology2025
Long non-coding RNA-based single and combination independent prognostic biomarkers for hepatocellular carcinoma.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Although significant advances have been made in the prevention and therapy, hepatocellular carcinoma (HCC) is still one of the most frequent and fatal human cancers worldwide. Discovery of independent prognostic biomarkers for the early identification and timely treatment of HCC patients with poor prognosis remains a key goal to achieve better patient survival. Long non-coding RNA (lncRNA) is one of the most-investigated classes of non-coding RNAs and plays important roles in controlling the occurrence and development of HCC through regulation of oncogene and tumor suppressor gene expression. Moreover, alterations in the expression levels of many lncRNAs are frequently observed in tumor tissues and blood circulation of HCC patients. LncRNAs have emerged as potential independent biomarkers for predicting the prognosis of HCC patients. This review comprehensively summarizes the evidence in the literature validating a single or a combination of lncRNA biomarker(s) with independent prognostic value in HCC patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.